Adamis Pharmaceuticals Corp. (NASDAQ:ADMP)’s share price rose 5.8% during trading on Friday . The company traded as high as $3.32 and last traded at $3.28, with a volume of 142,948 shares. The stock had previously closed at $3.10.

Separately, Maxim Group lifted their price objective on shares of Adamis Pharmaceuticals Corp. from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th.

The company has a 50-day moving average price of $4.73 and a 200-day moving average price of $5.73. The stock’s market capitalization is $49.54 million.

In related news, SVP David J. Marguglio sold 4,860 shares of the business’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $10.00, for a total value of $48,600.00. Following the completion of the transaction, the senior vice president now directly owns 106,227 shares in the company, valued at approximately $1,062,270. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP David J. Marguglio sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.08, for a total transaction of $32,320.00. Following the completion of the transaction, the senior vice president now owns 102,227 shares of the company’s stock, valued at $825,994.16. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.